FULGENT GENETICS, INC. Payments to Acquire Marketable Securities
FULGENT GENETICS, INC. (FLGT) reported Payments to Acquire Marketable Securities of $10.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-07-30
- FULGENT GENETICS, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $0.00.
- FULGENT GENETICS, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $10.01M.
- FULGENT GENETICS, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $61.96M, a 36.91% decline year-over-year.
- FULGENT GENETICS, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $18.88M, a 83.64% decline year-over-year.
- FULGENT GENETICS, INC. payments to acquire marketable securities for fiscal 2025 was $80.84M, a 82.89% decline from fiscal 2024.
- FULGENT GENETICS, INC. payments to acquire marketable securities for fiscal 2024 was $472.42M, a 3.96% decline from fiscal 2023.
- FULGENT GENETICS, INC. payments to acquire marketable securities for fiscal 2023 was $491.91M, a 17.69% increase from fiscal 2022.
- FULGENT GENETICS, INC. payments to acquire marketable securities for fiscal 2022 was $417.98M, a 41.17% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $10.01M 10-Q · filed 2026-07-30 | $71.97M derived: sum of 3 quarters · filed 2026-07-30 | $90.85M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $10.01M 10-Q · filed 2026-05-01 | $71.97M derived: sum of 2 quarters · filed 2026-05-01 | $90.85M derived: sum of 3 quarters · filed 2026-05-01 | $90.85M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $61.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $80.84M derived: sum of 2 quarters · filed 2026-02-27 | $80.84M derived: sum of 3 quarters · filed 2026-07-30 | $80.84M 10-K · filed 2026-02-27 |
| 2025-09-30 | $18.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $18.88M derived: sum of 2 quarters · filed 2026-07-30 | $18.88M 10-Q · filed 2025-11-07 | $117.08M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $0.00 10-Q · filed 2026-07-30 | $98.21M derived: sum of 3 quarters · filed 2026-07-30 | $213.59M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-01 | $98.21M derived: sum of 2 quarters · filed 2026-05-01 | $213.59M derived: sum of 3 quarters · filed 2026-05-01 | $276.67M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $98.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $213.59M derived: sum of 2 quarters · filed 2026-02-27 | $276.67M derived: sum of 3 quarters · filed 2026-02-27 | $472.42M 10-K · filed 2026-02-27 |
| 2024-09-30 | $115.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $178.47M derived: sum of 2 quarters · filed 2025-11-07 | $374.21M 10-Q · filed 2025-11-07 | $522.52M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $63.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $258.83M 10-Q · filed 2025-08-01 | $407.14M derived: sum of 3 quarters · filed 2026-02-27 | $500.21M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $195.74M 10-Q · filed 2025-05-02 | $344.05M derived: sum of 2 quarters · filed 2026-02-27 | $437.12M derived: sum of 3 quarters · filed 2026-02-27 | $543.73M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $148.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $241.38M derived: sum of 2 quarters · filed 2026-02-27 | $347.99M derived: sum of 3 quarters · filed 2026-02-27 | $491.91M 10-K · filed 2026-02-27 |
| 2023-09-30 | $93.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $199.68M derived: sum of 2 quarters · filed 2024-11-08 | $343.60M 10-Q · filed 2024-11-08 | $504.32M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $106.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $250.54M 10-Q · filed 2024-08-02 | $411.25M derived: sum of 3 quarters · filed 2025-02-28 | $423.03M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $143.93M 10-Q · filed 2024-05-03 | $304.64M derived: sum of 2 quarters · filed 2025-02-28 | $316.42M derived: sum of 3 quarters · filed 2025-02-28 | $431.77M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $160.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $172.49M derived: sum of 2 quarters · filed 2025-02-28 | $287.85M derived: sum of 3 quarters · filed 2025-02-28 | $417.98M 10-K · filed 2025-02-28 |
| 2022-09-30 | $11.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $127.13M derived: sum of 2 quarters · filed 2023-11-03 | $257.27M 10-Q · filed 2023-11-03 | $443.82M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $115.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $245.49M 10-Q · filed 2023-08-04 | $432.04M derived: sum of 3 quarters · filed 2024-02-28 | $531.17M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $130.13M 10-Q · filed 2023-05-05 | $316.68M derived: sum of 2 quarters · filed 2024-02-28 | $415.82M derived: sum of 3 quarters · filed 2024-02-28 | $621.15M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $186.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $285.68M derived: sum of 2 quarters · filed 2024-02-28 | $491.02M derived: sum of 3 quarters · filed 2024-02-28 | $710.49M 10-K · filed 2024-02-28 |
| 2021-09-30 | $99.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $304.47M derived: sum of 2 quarters · filed 2022-11-07 | $523.94M 10-Q · filed 2022-11-07 | $834.74M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $205.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $424.81M 10-Q · filed 2022-08-04 | $735.60M derived: sum of 3 quarters · filed 2023-02-28 | $736.78M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $219.47M 10-Q · filed 2022-05-05 | $530.27M derived: sum of 2 quarters · filed 2023-02-28 | $531.44M derived: sum of 3 quarters · filed 2023-02-28 | $535.84M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $310.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $311.97M derived: sum of 2 quarters · filed 2023-02-28 | $316.37M derived: sum of 3 quarters · filed 2023-02-28 | $324.36M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $5.57M derived: sum of 2 quarters · filed 2021-11-09 | $13.56M 10-Q · filed 2021-11-09 | $53.79M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $4.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $12.39M 10-Q · filed 2021-08-10 | $52.62M derived: sum of 3 quarters · filed 2022-02-28 | $54.29M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $7.99M 10-Q · filed 2021-05-07 | $48.22M derived: sum of 2 quarters · filed 2022-02-28 | $49.89M derived: sum of 3 quarters · filed 2022-02-28 | $54.08M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $40.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $41.90M derived: sum of 2 quarters · filed 2022-02-28 | $46.09M derived: sum of 3 quarters · filed 2022-02-28 | $52.08M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $5.86M derived: sum of 2 quarters · filed 2020-11-09 | $11.85M 10-Q · filed 2020-11-09 | $22.87M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $4.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $10.18M 10-Q · filed 2020-08-05 | $21.20M derived: sum of 3 quarters · filed 2020-08-05 | $22.89M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $5.99M 10-Q · filed 2020-05-06 | $17.01M derived: sum of 2 quarters · filed 2020-05-06 | $18.70M derived: sum of 3 quarters · filed 2020-05-06 | $25.49M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $11.02M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $12.72M derived: sum of 2 quarters · filed 2020-03-13 | $19.50M derived: sum of 3 quarters · filed 2020-03-13 | $24.19M 10-K · filed 2020-03-13 |
| 2018-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $8.48M derived: sum of 2 quarters · filed 2019-11-08 | $13.16M 10-Q · filed 2019-11-08 | $19.57M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $6.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $11.47M 10-Q · filed 2019-08-12 | $17.88M derived: sum of 3 quarters · filed 2019-08-12 | $19.55M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $4.68M 10-Q · filed 2019-05-10 | $11.09M derived: sum of 2 quarters · filed 2019-05-10 | $12.76M derived: sum of 3 quarters · filed 2019-05-10 | $13.56M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | $6.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $8.08M derived: sum of 2 quarters · filed 2019-03-22 | $8.88M derived: sum of 3 quarters · filed 2019-03-22 | $11.66M 10-K · filed 2019-03-22 |
| 2017-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $2.47M derived: sum of 2 quarters · filed 2018-11-09 | $5.25M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $802.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $3.58M 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | $2.78M 10-Q · filed 2018-05-14 | |||
| 2016-12-31 | $39.02M 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |